Get the Stockscreener App
0.863
7.70%
-0.072
After Hours:
.86
-0.003
-0.35%
Casi Pharmaceuticals Inc stock is traded at $0.863, with a volume of 18,171.
It is down -7.70% in the last 24 hours and down -40.48% over the past month.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
See More
Previous Close:
$0.935
Open:
$0.935
24h Volume:
18,171
Relative Volume:
0.16
Market Cap:
$17.73M
Revenue:
$31.56M
Net Income/Loss:
$-46.89M
P/E Ratio:
-0.2845
EPS:
-3.0329
Net Cash Flow:
$-26.70M
1W Performance:
-10.11%
1M Performance:
-40.48%
6M Performance:
-51.79%
1Y Performance:
-71.89%
1-Day Range:
$0.8501
$0.9387
1-Week Range:
$0.8011
$1.0499
52-Week Range:
$0.8011
$3.47
Casi Pharmaceuticals Inc Stock (CASI) Company Profile
Name
Casi Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare CASI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CASI
Casi Pharmaceuticals Inc
|
0.863 | 19.21M | 31.56M | -46.89M | -26.70M | -3.0329 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Initiated | Mizuho | Buy |
| Oct-23-20 | Initiated | Oppenheimer | Outperform |
| Sep-22-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Resumed | H.C. Wainwright | Buy |
| Jun-23-15 | Initiated | H.C. Wainwright | Buy |
View All
Casi Pharmaceuticals Inc Stock (CASI) Latest News
CASI Pharmaceuticals, Inc. announced that it expects to receive $20 million in funding from Emerging Technology Partners, LLC - marketscreener.com
CASI Pharmaceuticals secures $20 million funding for transplant rejection study - Investing.com
CASI Pharmaceuticals Secures $20 Million for Renal AMR Study - TipRanks
CASI Pharmaceuticals secures $20 million funding for transplant rejection study By Investing.com - Investing.com South Africa
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing - The Joplin Globe
CASI Pharmaceuticals (NASDAQ: CASI) plans $20 million notes to fund China AMR trial - Stock Titan
CASI Pharmaceuticals reports positive phase 1 data for ITP treatment - Investing.com
CASI Pharmaceuticals reports positive phase 1 data for ITP treatment By Investing.com - Investing.com Australia
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting - ACCESS Newswire
Casi Pharmaceuticals announces CID-103 immune thrombocytopenia study results - MSN
How sustainable is CASI Pharmaceuticals Inc. stock dividend payoutEarnings Trend Report & Verified Technical Trade Signals - Newser
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES - GuruFocus
CASI Pharmaceuticals, Inc. (CASI) 6.93% in After-hours: What’s Driving the Move? - Stocks Telegraph
Hedge Fund Moves: What margin trends mean for CASI Pharmaceuticals Inc. stockWeekly Profit Analysis & Weekly Watchlist for Hot Stocks - moha.gov.vn
CASI Pharmaceuticals Announces Changes in Board Governance - Investing News Network
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results - Investing News Network
CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ - Investing News Network
Lacklustre Performance Is Driving CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) 27% Price Drop - simplywall.st
CASI Pharmaceuticals Inc. (CASI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Casi Pharmaceuticals appoints James Huang as non-executive chairman - MSN
CASI Pharmaceuticals Appoints James Huang as Non-Executive Chairman - The Globe and Mail
How resilient is CASI Pharmaceuticals Inc. stock in market downturns2025 Key Lessons & Long-Term Capital Growth Strategies - newser.com
How CASI Pharmaceuticals Inc. stock performs in weak economyGap Up & Daily Growth Stock Tips - newser.com
How to read the order book for CASI Pharmaceuticals Inc.2025 Market Outlook & Weekly Top Gainers Alerts - newser.com
Is CASI Pharmaceuticals Inc. stock gaining market shareJuly 2025 Trends & Growth Oriented Trade Recommendations - newser.com
Is CASI Pharmaceuticals Inc. stock a top momentum playMarket Performance Summary & Weekly High Potential Alerts - newser.com
[6-K] CASI Pharmaceuticals, Inc. Current Report (Foreign Issuer) | CASI SEC FilingForm 6-K - Stock Titan
CASI Pharmaceuticals (NASDAQ: CASI) appoints James Huang Non-Executive Chairman - Stock Titan
CASI Pharmaceuticals Names James Huang Non-Executive Chairman of Board - marketscreener.com
What MACD and RSI say about CASI Pharmaceuticals Inc.2025 Macro Impact & Fast Entry Momentum Alerts - newser.com
Smart tools for monitoring CASI Pharmaceuticals Inc.’s price actionTrade Analysis Summary & Safe Swing Trade Setups - newser.com
Is CASI Pharmaceuticals Inc. stock attractive for retirement portfoliosTrade Performance Summary & Consistent Profit Focused Trading Strategies - newser.com
Can CASI Pharmaceuticals Inc. stock resist sector downturnsBuy Signal & Expert Approved Momentum Trade Ideas - newser.com
Will CASI Pharmaceuticals Inc. stock attract more institutional investorsChart Signals & Capital Protection Trade Alerts - newser.com
CASI Pharmaceuticals Stumbles On Revenue Drop And Nasdaq Challenge - Finimize
CASI Pharmaceuticals Reports Q3 2025 Results Amid Nasdaq Delisting Appeal - MSN
Casi Pharmaceuticals Inc Stock (CASI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):